- CLINICAL CORE The Mayo ADRC Clinical Core recruits, evaluates and follows longitudinally persons with cognitive disorders as well as cognitively normal persons who serve as controls. The Clinical Core is led by 4 behavioral neurologists (one in Jacksonville and 3 in Rochester) who have considerable expertise in the cognitive syndromes of the Alzheimer's disease (AD) and non-Alzheimer degenerative spectrum, as well as the cerebrovascular spectrum. In the past 4 years, the Mayo ADRC has made significant contributions in the areas of genetics and imaging of AD, the genetics, imaging and clinical characterization of the syndromes of frontotemporal lobar degeneration, and the clinical and imaging characterization of Dementia with Lewy Bodies. We have participated in numerous national consortia for clinical trials (industry and ADCS), genetics (ADGC) and imaging (ADNI). We have had excellent success with recruiting and retaining our research participants. In the past 4 years, we have recruited African American participants into a variety of projects and trials. Moreover, in conjunction with our Outreach, Recruitment and Education Core, we have a great increase in the number of African American participants who have agreed to brain donation after death. Although we do not require autopsy consent from our participants, our overall autopsy rate was 54%. For the new grant cycle, we intend to continue our activities in these focus areas. Thus, our specific aims include recruiting and following persons in the AD degenerative spectrum, persons with Dementia with Lewy Bodies and persons with frontotemporal lobar degeneration (FTLD) spectrum from preclinical to dementia. We will also recruit cognitively normal volunteers who agree to undergo brain imaging and cognitively normal persons with sleep disorders such as REM Sleep Behavior Disorder that are known to be predictive of synucleinopathy. This latter group will be recruited in order to address an understudied area, namely the preclinical manifestations of Lewy Body Disease. Our interest in this unique group of individuals takes advantage of our longstanding involvement in both mild cognitive impairment and in the Lewy Body Disease spectrum. We will also devote the necessary resources and effort for enhancing our recruiting and following of African American normal volunteers and patients with disorders in the AD, DLB and FTLD spectra. In support of another of our aims, we will obtain DNA on cognitively normal, MCI and dementia participants (AD, LBD, FTLD) in order to supply ADRC-related genetics projects with genetic material. All of the persons who are recruited and followed by the Mayo ADRC will have an evaluation by a behavioral neurologist, a neuropsychological assessment battery that includes the UDS as well as additional procedures, and multimodal brain imaging for the majority of participants. The Clinical Core will continue to work closely with the Neuropathology Core and ADRC related projects that require clinical- pathological correlation.

Public Health Relevance

- CLINICAL CORE The Mayo ADRC Clinical Core is the interface between our research enterprise and our patients. Our participants are extraordinarily well-studied, enabling detailed clinical-imaging-pathological correlations. The Clinical Core activities are a test-bed for improving clinical diagnosis of cognitive disorders.

Agency
National Institute of Health (NIH)
Institute
National Institute on Aging (NIA)
Type
Specialized Center (P50)
Project #
2P50AG016574-16
Application #
8676247
Study Section
Special Emphasis Panel (ZAG1)
Project Start
2014-05-01
Project End
2019-04-30
Budget Start
2014-05-01
Budget End
2015-04-30
Support Year
16
Fiscal Year
2014
Total Cost
Indirect Cost
Name
Mayo Clinic, Rochester
Department
Type
DUNS #
City
Rochester
State
MN
Country
United States
Zip Code
55905
Vassilaki, Maria; Aakre, Jeremiah A; Syrjanen, Jeremy A et al. (2018) Mediterranean Diet, Its Components, and Amyloid Imaging Biomarkers. J Alzheimers Dis 64:281-290
Zhao, Na; Liu, Chia-Chen; Van Ingelgom, Alexandra J et al. (2018) APOE ?2 is associated with increased tau pathology in primary tauopathy. Nat Commun 9:4388
Crum, Jana; Wilson, Jeffrey; Sabbagh, Marwan (2018) Does taking statins affect the pathological burden in autopsy-confirmed Alzheimer's dementia? Alzheimers Res Ther 10:104
Mordes, Daniel A; Prudencio, Mercedes; Goodman, Lindsey D et al. (2018) Dipeptide repeat proteins activate a heat shock response found in C9ORF72-ALS/FTLD patients. Acta Neuropathol Commun 6:55
Burke, Shanna L; Cadet, Tamara; Maddux, Marlaina (2018) Chronic Health Illnesses as Predictors of Mild Cognitive Impairment Among African American Older Adults. J Natl Med Assoc 110:314-325
Zhan, Yiqiang; Clements, Mark S; Roberts, Rosebud O et al. (2018) Association of telomere length with general cognitive trajectories: a meta-analysis of four prospective cohort studies. Neurobiol Aging 69:111-116
Lowe, Val J; Bruinsma, Tyler J; Min, Hoon-Ki et al. (2018) Elevated medial temporal lobe and pervasive brain tau-PET signal in normal participants. Alzheimers Dement (Amst) 10:210-216
Kamara, Dennis M; Gangishetti, Umesh; Gearing, Marla et al. (2018) Cerebral Amyloid Angiopathy: Similarity in African-Americans and Caucasians with Alzheimer's Disease. J Alzheimers Dis 62:1815-1826
Sassi, Celeste; Nalls, Michael A; Ridge, Perry G et al. (2018) Mendelian adult-onset leukodystrophy genes in Alzheimer's disease: critical influence of CSF1R and NOTCH3. Neurobiol Aging 66:179.e17-179.e29
Davis, Jeremy J (2018) Performance validity in older adults: Observed versus predicted false positive rates in relation to number of tests administered. J Clin Exp Neuropsychol 40:1013-1021

Showing the most recent 10 out of 1014 publications